Literature DB >> 34185

Antipsychotic effect of propranolol on chronic schizophrenics: study of a gradual treatment regimen.

A Elizur, Z Segal, A Yeret, S Davidson, A Atsmon.   

Abstract

Ten chronic treatment-resistant schizophrenic patients were treated in a single-blind trial for six weeks with propranolol in daily doses increasing up to 3 g in order to evaluate a modified dose regimen of propranolol treatment in these patients. Four of the patients improved significantly and could be released from the hospital, regaining premorbid social and work adjustments. The modified regimen proved safe as long as the dose increment was not more than 80 mg/day. The mean therapeutic level of propranolol was 1600 mg/day, which proved to be a safe dose. Although three patients with hypertensive encephalophaty responded, their response was related not to the maximum dose but to a drastic change in the rate of the dose increase. It seems that on the basis of these results a double-blind comparative study would be worthwhile.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 34185     DOI: 10.1007/bf00432292

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  6 in total

1.  The short-term effects of adrenergic-blocking agents in a small group of psychotic patients. Preliminary clinical observations.

Authors:  A Atsmon; I Blum; H Wijsenbeek; B Maoz; M Steiner; G Ziegelman
Journal:  Psychiatr Neurol Neurochir       Date:  1970 May-Jun

2.  Further studies with propranolol in psychotic patients. Relation to initial psychiatric state, urinary catecholamines and 3-methoxy-4-hydroxyphenylglycol excretion.

Authors:  A Atsmon; I Blum; M Steiner; A Latz; H Wijsenbeek
Journal:  Psychopharmacologia       Date:  1972

3.  Propranolol versus chlorpromazine in the treatment of psychoses associated with childbearing.

Authors:  M Steiner; A Latz; I Blum; A Atsmon; H Wijsenbeek
Journal:  Psychiatr Neurol Neurochir       Date:  1973 Nov-Dec

4.  [The effects of adrenergic blocking agents on psychotic patients].

Authors:  A Atsmon; I Blum; B Maoz; M Steiner; H Wysenbeek
Journal:  Harefuah       Date:  1970-07-01

5.  Safeguards in the treatment of schizophrenia with propranolol.

Authors:  N J Yorkston; S A Zaki; J F Themen; C W Havard
Journal:  Postgrad Med J       Date:  1976       Impact factor: 2.401

6.  Propranolol in the control of schizophrenic symptoms.

Authors:  N J Yorkston; S A Zaki; M K Malik; R C Morrison; C W Havard
Journal:  Br Med J       Date:  1974-12-14
  6 in total
  4 in total

Review 1.  [Use of certain cardiological drugs in the treatment of schizophrenia: review of the literature].

Authors:  P M Llorca; M A Wolf
Journal:  J Psychiatry Neurosci       Date:  1991-03       Impact factor: 6.186

2.  Involvement of central beta-adrenoceptors in the regulation of yawning responses.

Authors:  K Yamada; S Matsumoto; M Nagashima; M Kumagai; H Kimura; T Furukawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

3.  Are blood pressure surges associated with sympathetic stimulation aggravated by beta-adrenoceptor antagonist treatment?

Authors:  C R Kumana
Journal:  Postgrad Med J       Date:  1986-08       Impact factor: 2.401

4.  Efficacy of propranolol on schizophrenic thought disorder.

Authors:  B B Sethi; S Dube
Journal:  Indian J Psychiatry       Date:  1981-10       Impact factor: 1.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.